Atrás
27
También listada como
HKMPF
OTC
Rango del Día
$32.98
$34.88
Rango de 52 Semanas
$31.80
$56.94
Volumen
550
Promedio 50D / 200D
$39.84
/
$45.96
Cierre Anterior
$34.13
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (626 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | 9.0 | 0.4 |
| P/B | 1.4 | 2.9 |
| ROE % | 16.4 | 3.7 |
| Net Margin % | 12.0 | 3.9 |
| Rev Growth 5Y % | 7.1 | 10.0 |
| D/E | 0.6 | 0.2 |
Precio Objetivo de Analistas
No hay cobertura de analistas disponible
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2027 |
$0.00
$0.00 – $0.00
|
3.6 B | 0 |
| FY2026 |
$0.00
$0.00 – $0.00
|
3.5 B | 0 |
Puntos Clave
Revenue grew 7.08% annually over 5 years — modest growth
ROE of 16.44% — decent returns on equity
Generating 162.38M in free cash flow
P/E of 9.01 — trading at a low valuation
PEG of 0.89 suggests growth is underpriced
Capital efficient — spends only 5.88% of revenue on capex
Crecimiento
Revenue Growth (5Y)
7.08%
Revenue (1Y)7.35%
Earnings (1Y)12.24%
FCF Growth (3Y)-36.60%
Calidad
Return on Equity
16.44%
ROIC11.06%
Net Margin12.00%
Op. Margin18.63%
Seguridad
Debt / Equity
0.64
Current Ratio1.82
Interest Coverage5.89
Valoración
P/E Ratio
9.01
P/B Ratio1.40
EV/EBITDA7.92
Dividend Yield0.04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7.35% | Revenue Growth (3Y) | 8.06% |
| Earnings Growth (1Y) | 12.24% | Earnings Growth (3Y) | 45.63% |
| Revenue Growth (5Y) | 7.08% | Earnings Growth (5Y) | -1.09% |
| Profitability | |||
| Revenue (TTM) | 3.36B | Net Income (TTM) | 402.94M |
| ROE | 16.44% | ROA | 7.11% |
| Gross Margin | 40.04% | Operating Margin | 18.63% |
| Net Margin | 12.00% | Free Cash Flow (TTM) | 162.38M |
| ROIC | 11.06% | FCF Growth (3Y) | -36.60% |
| Safety | |||
| Debt / Equity | 0.64 | Current Ratio | 1.82 |
| Interest Coverage | 5.89 | Dividend Yield | 0.04% |
| Valuation | |||
| P/E Ratio | 9.01 | P/B Ratio | 1.40 |
| P/S Ratio | 1.08 | PEG Ratio | 0.89 |
| EV/EBITDA | 7.92 | Dividend Yield | 0.04% |
| Market Cap | 3.63B | Enterprise Value | 4.95B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.36B | 3.13B | 2.88B | 2.52B | 2.55B |
| Net Income | 402.94M | 359.00M | 190.00M | 188.00M | 421.00M |
| EPS (Diluted) | 3.62 | 3.22 | 1.72 | 1.68 | 3.62 |
| Gross Profit | 1.34B | 1.42B | 1.41B | 1.24B | 1.30B |
| Operating Income | 625.46M | 612.00M | 367.00M | 282.00M | 582.00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 5.67B | 5.13B | 4.68B | 4.47B | 4.37B |
| Total Liabilities | 3.07B | 2.81B | 2.47B | 2.32B | 1.91B |
| Shareholders' Equity | 2.59B | 2.31B | 2.20B | 2.14B | 2.45B |
| Total Debt | 1.65B | 1.31B | 1.19B | 1.28B | 846.00M |
| Cash & Equivalents | 328.00M | 188.00M | 205.00M | 270.00M | 426.00M |
| Current Assets | 2.64B | 2.26B | 2.10B | 2.00B | 2.09B |
| Current Liabilities | 1.45B | 1.98B | 1.34B | 1.08B | 1.02B |
Puntuaciones de Estrategias
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#349 of 658
Actividad Reciente
Entró
Contrarian Investing (David Dreman)
Mar 24, 2026